iRhythm has posted four straight earnings beats with average quarterly outperformance exceeding 140%, is growing revenue at 26% year-over-year, and carries analyst-implied upside of roughly 37% — but a confirmed price downtrend, a pending legal proceeding, and a critical event disclosure currently block a clean setup and warrant a watchful posture rather than an immediate position.
Thesis pillars
- Perfect Earnings Beat Streak↓Deteriorating
- Strong Revenue Growth Trajectory↓Deteriorating
- Critical Events Legal Risk Overhang↑Improving
- +1 more pillar — see the Why tab for full reasoning
iRhythm Holdings, Inc. (IRTC) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $126.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 3.9): -1.5.
iRhythm Holdings commercializes Zio patch-based cardiac monitors (Zio monitor, Zio XT, Zio AT) that record up to 14 days of continuous ECG data and bills Medicare (24% of 2025 revenue) and commercial payors through company-operated IDTFs. iRhythm holds approximately 40%... Read more
Hold if already holding. Not a fresh buy at $126.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 3.9): -1.5. Chart setup: Death cross but MACD improving, RSI 65. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.9/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news boost analyst 0.60, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and SEC filing concern. Suitability: speculative.
About iRhythm Holdings, Inc.
About iRhythm Holdings, Inc.
The Zio monitor, Zio XT, and Zio AT — iRhythm Holdings' three FDA-cleared patch-based cardiac monitors — generate substantially all of the company's revenue through long-term continuous monitoring (LTCM) and mobile cardiac telemetry (MCT) services billed to Medicare (approximately 24% of 2025 revenue) and commercial payors. The company employed approximately 2,400 regular full-time employees at December 31, 2025 and has delivered more than 12 million patient reports since inception, holding approximately 40% penetration of the U.S. ambulatory cardiac monitoring market.
iRhythm earns fee-for-service reimbursement from Medicare and commercial payors for LTCM and MCT services performed through its Medicare-enrolled IDTFs. CMS updates national payment rates annually via the Medicare Physician Fee Schedule; effective January 1, 2026, rates for CPT codes 93247, 93243, and 93229 increased versus 2025, though future year-over-year increases are not guaranteed. Distribution is direct-to-physician: ordering physicians apply Zio patches, patients return the device to iRhythm's IDTF, and proprietary FDA-cleared deep-learning algorithms process ECG data before qualified technicians validate and transmit reports via the ZioSuite portal or EHR connections. Competitors named in the filing include GE Healthcare, Philips Healthcare, BioTelemetry (now part of Royal Philips), and Preventice Solutions (now part of Boston Scientific).
Show full overview
Three Medicare Administrative Contractors — Noridian Healthcare Solutions, Palmetto GBA, and CGS Administrators — published proposed local coverage determinations in September 2025 regarding ambulatory cardiac monitoring, with a public comment period closing November 2025. If adopted in a restrictive form, these LCDs could require iRhythm to revise its business model, billing processes, and compliance controls. CMS may also reduce CPT code reimbursement rates in future years, and commercial payors may terminate contracts with prior written notice, exposing the company to concentrated revenue risk from key payer relationships.
See also: Healthcare · Medical Devices
From iRhythm Holdings, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-08-15Recent Developments — iRhythm Holdings, Inc.
Latest news
- NEWS Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - TradingView — TradingView negative
- NEWS Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - tradingview.com — tradingview.com negative
- NEWS IRTC|iRhythm Technologies Inc|Price:119.140|Chg%:-3.300 - TradingKey — TradingKey neutral
- NEWS IRTC|iRhythm Technologies Inc|Price:119.140|Chg%:-3.300 - tradingkey.com — tradingkey.com neutral
- NEWS iRhythm Holdings (IRTC) Could Be 34% Undervalued Following Its Recent Rebound - simplywall.st — simplywall.st positive
Generated 2026-08-15T11:32:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductiRhythm Services10-K Item 1A: 'reimbursement for our iRhythm Services will account for substantially all our revenue for the foreseeable future'
- LOWCustomerMedicare program24%10-K Item 1A: 'we received approximately 24% of our total revenue from the Medicare program through CMS'
Material Events(8-K, last 90d)
- 2026-04-01Item 4.01HIGHPricewaterhouseCoopers LLP dismissed as independent auditor effective March 30, 2026. No disagreements or reportable events cited. Successor auditor not named in this filing.SEC filing →
- 2026-03-12Item 5.02LOWJason Patten appointed as independent director and Audit Committee member effective March 12, 2026. Board-determined independent; no prior arrangements or material interests cited.SEC filing →
- 2026-05-28Item 5.02LOWStockholders approved the iRhythm Holdings 2026 Equity Incentive Plan at the May 27, 2026 Annual Meeting, replacing the 2016 Equity Incentive Plan. No director departure or officer change cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $126.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 3.9): -1.5. Chart setup: Death cross but MACD improving, RSI 65. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $153.87 (+21.7%), stop $117.59 (−7.5%), A.R:R 1.4:1. Score 5.9/10, moderate confidence.
Take-profit target: $153.87 (+21.7% upside). Target $153.87 (+21.7%), stop $117.59 (−7.5%), A.R:R 1.4:1. Stop-loss: $117.59.
Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 3.9): -1.5; Elevated risk factors.
iRhythm Holdings, Inc. trades at a P/E of N/A (forward 103.2). TrendMatrix value score: 6.5/10. Verdict: Hold.
21 analysts cover IRTC with a consensus score of 4.4/5. Average price target: $177.
What does iRhythm Holdings, Inc. do?iRhythm Holdings commercializes Zio patch-based cardiac monitors (Zio monitor, Zio XT, Zio AT) that record up to 14...
iRhythm Holdings commercializes Zio patch-based cardiac monitors (Zio monitor, Zio XT, Zio AT) that record up to 14 days of continuous ECG data and bills Medicare (24% of 2025 revenue) and commercial payors through company-operated IDTFs. iRhythm holds approximately 40% penetration of the U.S. long-term continuous monitoring market.